INDOCO REMEDIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 300.4 INR | -3.25% |
|
-3.39% | -23.98% |
| 22/05 | Indoco Remedies Gets Final Nod from US FDA for Pregabalin Capsules | MT |
| 21/05 | Indoco Remedies Ltd. Receives Final ANDA Approval from USFDA for Pregabalin Capsules | CI |
| Sales 2024 | 18.17B 218M | Sales 2025 * | 19.74B 237M | Capitalization | 27.7B 332M |
|---|---|---|---|---|---|
| Net income 2024 | 985M 11.81M | Net income 2025 * | 1.36B 16.33M | EV / Sales 2024 | 1.67 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.4 x |
| P/E ratio 2024 |
31.3
x | P/E ratio 2025 * |
20.3
x | Employees | 6,000 |
| Yield 2024 * |
0.67% | Yield 2025 * |
0.62% | Free-Float | 34.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Indoco Remedies Limited
More press releases
| 1 day | -3.25% | ||
| 1 week | -3.39% | ||
| 1 month | -8.11% | ||
| 3 months | -13.96% | ||
| 6 months | -17.13% | ||
| Current year | -23.98% |
1 week
295.15
319.55
1 month
295.15345.25
Current year
295.15415.00
1 year
295.15415.00
3 years
295.15530.25
5 years
132.45530.25
10 years
132.45530.25
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 27/04/27 | |
Pramod Ghorpade
DFI | Director of Finance/CFO | - | 02/21/02 |
| Chairman | 85 | 02/63/02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 85 | 02/63/02 | |
| Director/Board Member | 63 | 01/82/01 | |
| Chief Executive Officer | 54 | 27/04/27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 300.4 | -3.25% | 728,095 |
| 30/24/30 | 310.6 | -0.53% | 167,658 |
| 29/24/29 | 312.2 | -0.84% | 55,925 |
| 28/24/28 | 314.8 | -0.97% | 139,518 |
| 27/24/27 | 318 | +2.23% | 312,871 |
Delayed Quote NSE India S.E., May 31, 2024 at 05:13 pm IST
More quotes
Indoco Remedies Limited is an India-based manufacturer of pharmaceutical products. The Company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The Company offers medicines in multiple therapeutic categories, such as diabetology, respiratory, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders and primary care medicine. Its products/brands include Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel among others. The Company caters to both domestic and international markets. Its subsidiaries include Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited.
Sector
Pharmaceuticals
Calendar
13/08/2024
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
300.4
INR
Average target price
356.4
INR
Spread / Average Target
+18.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.98% | 332M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- INDOCO Stock
